Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonist
- 30 November 1993
- Vol. 42 (5) , 533-535
- https://doi.org/10.1016/0090-4295(93)90265-c
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- LeuprorelinDrugs & Aging, 1991
- Sudden Death due to Disease Flare with Luteinizing Hormone-Releasing Hormone Agonist Therapy for Carcinoma of the ProstateJournal of Urology, 1990
- Clinical Study of Leuprolide Depot Formulation in the Treatment of Advanced Prostate CancerJournal of Urology, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Flutamide Eliminates the Risk of Disease Flare in Prostatic Cancer Patients Treated with a Luteinizing Hormone-Releasing Hormone AgonistJournal of Urology, 1987
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Androgen Suppression by a Gonadotropin Releasing Hormone Analogue in Patients with Metastatic Carcinoma of the ProstateJournal of Urology, 1984
- Physiologic Basis for Hormonal Therapy in Carcinoma of the ProstateUrologic Clinics of North America, 1975
- Estrogen treatment for cancer of the prostate.Early results with 3 doses of diethylstilbestrol and placeboCancer, 1970